<DOC>
	<DOC>NCT02486406</DOC>
	<brief_summary>The purpose of this three part study is to evaluate the pharmacokinetics (Part 1), safety/efficacy (Part 2), and long-term follow-up (Part 3) of ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in pediatric subjects with genotype 1 or 4 chronic hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1. Positive antiHCV Ab and HCV RNA greater than or equal to 1000 IU/mL at the time of screening. 2. HCV genotype 1 for enrollment into Part 1 and genotype 1 or 4 for enrollment into Part 2. 3. Parent or legal guardian with the willingness and ability to provide written informed consent and participant willing and able to give assent, as appropriate for age and country. 1. Women who are pregnant, breastfeeding or are considering becoming pregnant 2. Use of known strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450 2C8 (CYP2C8) in participants receiving dasabuvir, or strong or moderate inducers of CYP3A, within 2 weeks or 10 half lives, whichever is longer, of the respective medication/supplement prior to study drug administration. 3. Positive test result for Hepatitis B surface antigen (HbsAg) or antiHIV antibody (HIV Ab) test. 4. Current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available antiHCV agents other than IFNs or RBV or receipt of any investigational product within 6 weeks prior to study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C Genotype 4</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>